Altimmune Inc (ALT)

$3.95 -0.01 (-0.25%)
Market Cap 349.50M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.09
Volume 1,931,700
Avg Vol 2,731,290
Day's Range N/A - N/A
Shares Out 88.26M
Stochastic %K 45%
Beta 0.07
Analysts Strong Sell
Price Target $17.75

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
Damnthisappilosthistory
Damnthisappilosthistory Oct. 25 at 4:16 PM
$ALT I was skeptical of the dark pool theory, but Bloomberg just posted this chart. Could it REALLY be that tutes are accumulating on dark pools, so the price stays low for them?
0 · Reply
DarbyCash
DarbyCash Oct. 25 at 4:02 PM
$ALT
0 · Reply
IBMHQ
IBMHQ Oct. 25 at 3:05 PM
$ALT The Lincoln affect (Under 5 dollars) and we’re between Phase 2 and 3 allowing MM to play their games. However, once the road is built buyers will be able to get on it (Buy shares) since they now know where it’s going (visualization of profit).
0 · Reply
drnopain
drnopain Oct. 25 at 2:34 PM
$ALT a deal will happen in the least expected time If you believe in the science and the results just buy and hold if you don’t save your energy by moving somewhere else Simple
3 · Reply
DavidT305
DavidT305 Oct. 25 at 11:56 AM
$ALT lly is ahead in glp1s for Mash, they’ve already started 2 phase 3 with both drugs. They have better data and know how to run clinical trials
1 · Reply
GreenEnergy2022
GreenEnergy2022 Oct. 25 at 11:17 AM
$ALT "The magnitude of increase depends heavily on company size, lead asset, indication, data quality, market expectations, and how much was already priced in." - Safe to say, that at 300mcap, not much is already priced in the stock. = This means that any positive driver, FDA EoP2, or good 48w data have a high likelihood of increasing the company valuation.
0 · Reply
BigElvis_GTown
BigElvis_GTown Oct. 25 at 10:49 AM
$ALT love to see a $5B+ deal before the end of 2025 for tax reasons. Takes some gains this year and roll my LT gains to 2026😎
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 10:26 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALT Current Share Price: $3.95 Contracts: $ALT January 15, 2027 $4 Calls Scale in: $1.59- $1.94 Scale out: $2.47-$3.18 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Bee_ST
Bee_ST Oct. 25 at 9:48 AM
$ALT why I think tutes hesitate to invest (Part 1/3) It’s not about the science — it’s about the stage. Altimmune sits between Phase 2 and Phase 3, a no-man’s-land many funds simply avoid until the FDA path is locked. The End-of-Phase-2 (EoP2) meeting hasn’t happened yet, so no one outside knows the agreed design, endpoints, or timeline. Until that’s clear, many healthcare funds are not even allowed to build positions under their risk policies. They wait for regulatory clarity — even if the price is higher later. That’s why you see small retail accumulation, but no big blocks yet.
5 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 8:25 AM
Enter: $ALT Calls Strike Price: $4 Expiry Date: NOV 14 2025 Buy in Price: $0.43 - $0.55 Sell Price: $0.70 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Latest News on ALT
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oct 20, 2025, 7:30 AM EDT - 5 days ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Oct 6, 2025, 10:09 AM EDT - 19 days ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 5, 2025, 11:40 PM EDT - 19 days ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 3, 2025, 9:50 AM EDT - 22 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 30, 2025, 10:20 AM EDT - 25 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 29, 2025, 7:30 AM EDT - 26 days ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Altimmune to Participate in Two Upcoming Investor Conferences

Sep 23, 2025, 7:30 AM EDT - 4 weeks ago

Altimmune to Participate in Two Upcoming Investor Conferences

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 21, 2025, 8:39 AM EDT - 4 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

Sep 19, 2025, 10:27 AM EDT - 5 weeks ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

SLQT

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Sep 18, 2025, 8:45 AM EDT - 5 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 15, 2025, 7:30 AM EDT - 5 weeks ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:20 AM EDT - 6 weeks ago

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Aug 27, 2025, 5:17 PM EDT - 2 months ago

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Altimmune to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:30 AM EDT - 2 months ago

Altimmune to Participate in Upcoming Investor Conferences

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 19, 2025, 7:30 AM EDT - 2 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 15, 2025, 12:06 PM EDT - 2 months ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:44 PM EDT - 2 months ago

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Aug 13, 2025, 2:57 PM EDT - 2 months ago

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Aug 12, 2025, 7:00 AM EDT - 2 months ago

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Altimmune Board of Directors Appoints Jerry Durso as Chairman

Aug 11, 2025, 7:30 AM EDT - 2 months ago

Altimmune Board of Directors Appoints Jerry Durso as Chairman

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Aug 5, 2025, 7:30 AM EDT - 2 months ago

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

Jul 19, 2025, 2:30 PM EDT - 3 months ago

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Jul 9, 2025, 7:30 AM EDT - 3 months ago

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

Jun 27, 2025, 2:39 PM EDT - 4 months ago

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

Altimmune: Deciphering The MASH Crash (Rating Upgrade)

Jun 26, 2025, 4:30 PM EDT - 4 months ago

Altimmune: Deciphering The MASH Crash (Rating Upgrade)

Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide

Jun 26, 2025, 2:59 PM EDT - 4 months ago

Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Jun 26, 2025, 8:16 AM EDT - 4 months ago

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

BTBT KTOS

Altimmune's weight-loss drug meets main goal in fatty liver disease trial

Jun 26, 2025, 7:43 AM EDT - 4 months ago

Altimmune's weight-loss drug meets main goal in fatty liver disease trial

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

Jun 26, 2025, 7:00 AM EDT - 4 months ago

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Jun 25, 2025, 7:12 PM EDT - 4 months ago

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Damnthisappilosthistory
Damnthisappilosthistory Oct. 25 at 4:16 PM
$ALT I was skeptical of the dark pool theory, but Bloomberg just posted this chart. Could it REALLY be that tutes are accumulating on dark pools, so the price stays low for them?
0 · Reply
DarbyCash
DarbyCash Oct. 25 at 4:02 PM
$ALT
0 · Reply
IBMHQ
IBMHQ Oct. 25 at 3:05 PM
$ALT The Lincoln affect (Under 5 dollars) and we’re between Phase 2 and 3 allowing MM to play their games. However, once the road is built buyers will be able to get on it (Buy shares) since they now know where it’s going (visualization of profit).
0 · Reply
drnopain
drnopain Oct. 25 at 2:34 PM
$ALT a deal will happen in the least expected time If you believe in the science and the results just buy and hold if you don’t save your energy by moving somewhere else Simple
3 · Reply
DavidT305
DavidT305 Oct. 25 at 11:56 AM
$ALT lly is ahead in glp1s for Mash, they’ve already started 2 phase 3 with both drugs. They have better data and know how to run clinical trials
1 · Reply
GreenEnergy2022
GreenEnergy2022 Oct. 25 at 11:17 AM
$ALT "The magnitude of increase depends heavily on company size, lead asset, indication, data quality, market expectations, and how much was already priced in." - Safe to say, that at 300mcap, not much is already priced in the stock. = This means that any positive driver, FDA EoP2, or good 48w data have a high likelihood of increasing the company valuation.
0 · Reply
BigElvis_GTown
BigElvis_GTown Oct. 25 at 10:49 AM
$ALT love to see a $5B+ deal before the end of 2025 for tax reasons. Takes some gains this year and roll my LT gains to 2026😎
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 10:26 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ALT Current Share Price: $3.95 Contracts: $ALT January 15, 2027 $4 Calls Scale in: $1.59- $1.94 Scale out: $2.47-$3.18 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Bee_ST
Bee_ST Oct. 25 at 9:48 AM
$ALT why I think tutes hesitate to invest (Part 1/3) It’s not about the science — it’s about the stage. Altimmune sits between Phase 2 and Phase 3, a no-man’s-land many funds simply avoid until the FDA path is locked. The End-of-Phase-2 (EoP2) meeting hasn’t happened yet, so no one outside knows the agreed design, endpoints, or timeline. Until that’s clear, many healthcare funds are not even allowed to build positions under their risk policies. They wait for regulatory clarity — even if the price is higher later. That’s why you see small retail accumulation, but no big blocks yet.
5 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 8:25 AM
Enter: $ALT Calls Strike Price: $4 Expiry Date: NOV 14 2025 Buy in Price: $0.43 - $0.55 Sell Price: $0.70 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
GreenEnergy2022
GreenEnergy2022 Oct. 25 at 7:51 AM
$ALT This is a very good mentality. Like how many dips do we have left to buy? I need more before takeoff
1 · Reply
12BeenedictCucumberbatch
12BeenedictCucumberbatch Oct. 25 at 7:35 AM
$ALT I wouldn't be opposed to the SEC having a check.
0 · Reply
12BeenedictCucumberbatch
12BeenedictCucumberbatch Oct. 25 at 7:28 AM
$ALT I am really
0 · Reply
Bee_ST
Bee_ST Oct. 25 at 5:58 AM
$ALT Just saying… 😉 Just because Sanofi says they’re not looking for a MASH drug… doesn’t mean they haven’t already found one.
1 · Reply
BioRich
BioRich Oct. 25 at 5:16 AM
$ALT Curious, if I was using my retirement account (IRAs) to hold shares of $ALT, would I still be considered an "investor" for the sake of this board? I don't want to misrepresent being an investor if holding them in a retirement account doesn't count. TIA
0 · Reply
BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
denzo2
denzo2 Oct. 25 at 4:51 AM
$ALT Just sayin..Four most recent MASH/obesity M&A deals Boston Pharma (FGF-21, MASH only), 89Bio (FGF-21, MASH only), Akero (FGF-21, MASH only) Metsera (biased GLP-1, obesity only), . Maybe now is time for BP to get into GLP-1/GCGG (MASH + obesity)??
1 · Reply
HoodyHaz
HoodyHaz Oct. 25 at 4:17 AM
$TPST $TPST Is First out of the gate then to $SLS $ALT 3 best buyout candidates!!
2 · Reply
HoodyHaz
HoodyHaz Oct. 25 at 4:05 AM
$SLS 3 most exciting buyout candidates… $SLS $ALT $TPST TPST 10x ALT 30x SLS 30x Great assets… Best Speculation Plays !! ALL VERY VERY SOON…One goes into the other 2…. Then your liftoff…
2 · Reply
Excessive_
Excessive_ Oct. 25 at 2:41 AM
$ALT When there is time to buy this sp doesn't rise. It can be manipulated. The only way the sp rises is if everybody wants in at the same time. Other than shorts and flippers there is currently no buying. News is needed to eiher create retail fomo, force shorts to cover quickly, or for tutes to pile in. The proper news will provide all at once.
1 · Reply
Lazarus2024
Lazarus2024 Oct. 25 at 1:28 AM
$ALT If the shorts are covering, why no squeeze?
3 · Reply
Rolf1968
Rolf1968 Oct. 25 at 1:07 AM
$ALT everyone relax as sure as fat girls are horny Garg has this in the bag
1 · Reply